Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 10, 2026 23:29 ET | Source: NeuroSalt

NeuroSalt Under Investigation: What the 2026 Formulation Transparency Review Reveals About Botanical Ingredients, Dosage Disclosure, and Consumer Verification

What a 2026 ingredient review of NeuroSalt's botanical nerve formula found — and the consumer verification questions most coverage skips.
April 10, 2026 22:53 ET | Source: Pulsetto

Pulsetto Claims Evaluated: 2026 Update on the Pulsetto Vagus Nerve Stimulator, Features, Pricing, and Consumer Use Considerations

Pulsetto vagus nerve stimulator 2026 update covering Lite vs FIT, pricing context, FCC certification, and consumer wellness use considerations.
April 10, 2026 21:13 ET | Source: Emma

Emma Relief Claims Evaluated: Rising Consumer Interest in Gut Health Formulas for Bloating and Digestive Support in 2026

Ingredient context, consumer considerations, and 2026 category positioning for Emma Relief, the daily gut health formula from Enclave BioActives.
April 10, 2026 19:41 ET | Source: Gentle Patches

Gentle Patches Claims Evaluated: 2026 Consumer Interest Rises Around Transdermal Wellness Patch Ingredients, Product Lineup, and Policy Transparency

Gentle Patches draws rising 2026 consumer interest as the pill-free transdermal wellness patch lineup highlights ingredient and policy details.
April 10, 2026 18:54 ET | Source: IVY Rx

IVY Rx Claims Evaluated: 2026 Compounded GLP-1 Telehealth Program Details, Monthly Pricing Structure, Clinician Access Model, and Patient Eligibility Information

IVY Rx releases 2026 compounded GLP-1 telehealth program information covering pricing tiers, clinician access, and pharmacy fulfillment details.
April 10, 2026 18:45 ET | Source: Hagens Berman Sobol Shapiro LLP

INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit– Hagens Berman

Investors who lost money in IBRX after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.